Clinical Trials Logo

Amblyopia clinical trials

View clinical trials related to Amblyopia.

Filter by:

NCT ID: NCT03610997 Active, not recruiting - Hyperopia Clinical Trials

Photorefractive Keratectomy for Severe Anisometropia and Isoametropia Associated With Amblyopia

Start date: January 1, 2001
Phase: N/A
Study type: Interventional

Photorefractive keratectomy (PRK) with excimer laser has been used successfully to treat myopia, hyperopia, and astigmatism in adults for over 35 years. Children with high refractive errors that go untreated will develop severe amblyopia. PRK can normalize high refractive errors and potentially improve the visual acuity in affected children. The purpose of this study is to investigate whether children with high anisometropia or isoametropia with amblyopia that are nonresponsive to standard therapy and receive PRK develop better longterm visual acuity.

NCT ID: NCT03608150 Completed - Amblyopia Clinical Trials

Luminopia One Amblyopia Vision Improvement Study

Start date: January 16, 2019
Phase: N/A
Study type: Interventional

The objective of the study is to demonstrate the safety and efficacy of Luminopia One in amblyopia patients with amblyopia associated with anisometropia and/or with mild strabismus.

NCT ID: NCT03505606 Active, not recruiting - Amblyopia Clinical Trials

New Visual Acuity and Crowding Tests for Better Detection of Amblyopia

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Amblyopia, or 'lazy eye', is the reduction in vision usually in one eye, due to abnormal visual development without organic cause. It is a preventable and leading cause of monocular vision loss (prevalence of around 3%) and increases lifetime risk of bilateral visual impairment from 10% in the general population, to 18% in amblyopes. In the UK, vision screening in children aims to detect amblyopia and other undiagnosed visual conditions. Laboratory research suggest that amblyopia could be better detected by modifying standard clinical vision tests to enhance and quantify "crowding". Crowding is the negative effect that surrounding features have on the visibility of a target. Crowding distance and crowding magnitude are considerably greater in amblyopic eyes than in normal healthy eyes. Modifications that should lead to improved amblyopia detection are 1) place letters closer together on a vision chart, 2) define letters by contrast, rather than luminance, and 3) use a new thinner font in the form of numbers, to allow crowding distance in central vision to be measured. In this project, these modifications will be tested in amblyopic children for the first time. Amblyopic children aged 3 to 11 years (n=32) will be recruited from ACPOS (Addenbrooke's Community Paediatric Ophthalmology Service) at ARU. They will have their vision measured with the three modified tests as well as an uncrowded test. The child will view letters and numbers on a computer screen and respond (verbally or by indicating their choice on a matching card). Testing is fun and game-like with breaks for rewards. Results will be compared to standard vision measurement (SLT: Sonksen LogMAR Test) from the child's ACPOS visit. Amblyopic data will be compared to control data from normal healthy children aged 3 to 11 years (n=200), and age-matched children with normal vision (n=16) from ACPOS (false referrals from school screening).

NCT ID: NCT03447171 Completed - Amblyopia Clinical Trials

Prospective Evaluation of a Smartphone Application, GoCheckKids™, to Detect Amblyopia Risk Factors in Young Children

Start date: February 7, 2018
Phase:
Study type: Observational

The objective is evaluation of GoCheck Kids, a smartphone application ('App'), for use as a photo screening device in a pediatric population to detect amblyopia risk factors (ARFs).

NCT ID: NCT03402789 Withdrawn - Amblyopia Clinical Trials

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

Start date: January 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the addition of docosahexaenoic acid (DHA) to eye patching in the treatment of residual amblyopia in children ages 3 to 18 years old. Two thirds of participants will receive DHA along with eye patching, while one third of participants will receive a placebo along with eye patching.

NCT ID: NCT03342235 Withdrawn - Refractive Errors Clinical Trials

Excimer Laser Surgery for Anisometropic Amblyopia

ATS19
Start date: June 2020
Phase: N/A
Study type: Interventional

Study Objectives To compare the efficacy and safety of surgical treatment (PRK) versus non-surgical treatment of anisometropic amblyopia in children who have failed conventional treatment due to non-compliance or non-response. Synopsis of Study Design The study consists of two phases: 1. A Patching Run-In Phase during which all participants are treated for at least 8 weeks with continued refractive correction (with spectacles and/or contact lenses) and patching prescribed 42 hours per week (averaging 6 hours daily) until no further improvement over 2 consecutive visits at least 4 weeks apart or the vision no longer meets eligibility criteria. 2. A Randomized Trial Phase, beginning after no further VA improvement in the patching run-in phase and qualifying amblyopia is still present, during which the participant is assigned to either surgery with PRK and patching prescribed 2 hours per day or to non-surgical treatment with continued refractive correction (with spectacles and/or contact lenses) and patching prescribed 2 hours per day.

NCT ID: NCT03341780 Completed - Amblyopia Clinical Trials

Standard Amblyopia Therapy in Adult Amblyopes

Start date: December 16, 2014
Phase: N/A
Study type: Observational

Amblyopia is characterized by a reduction in visual acuity, contrast sensitivity, and binocular visual functions. The two main causes of amblyopia are anisometropia and strabismus which alter the synaptic connections between neurons along the visual pathway. Current treatment for amblyopia has indicated that the younger the amblyope, the greater the effect of treatment. The purpose of this study is to determine if standard amblyopia treatment improved visual acuity in adult amblyopes.

NCT ID: NCT03288948 Recruiting - Amblyopia Clinical Trials

Binocular Amblyopia Treatment

Start date: August 31, 2017
Phase: N/A
Study type: Interventional

To evaluate the effectiveness of enhanced binocular amblyopia treatments in achieving a more complete and stable recovery.

NCT ID: NCT03255707 Completed - Amblyopia Clinical Trials

A Comparative Study Between Dissociative Treatment and Binocular Interactive Treatment in Amblyopia

Start date: November 24, 2016
Phase: N/A
Study type: Interventional

Amblyopia is a unilateral or, infrequently, a bilateral reduction of best corrected visual acuity which cannot be attributed to coexisting eye or visual pathway disease. Amblyopia can be due to eye-crossing occurring in early childhood or due to error of refraction whether a high difference between the two eyes or very high bilateral refractive errors.Another cause could be visual deprivation like the presence of congenital cataract. The prevalence of amblyopia worldwide is approximately 1%-5% .In Egypt, a study that was held in Upper Egypt, found that the prevalence of amblyopia was 1.49%, which is higher in rural areas than in urban areas. Several modalities of treatment for amblyopia are available, yet occlusion treatment is the gold standard involving covering the good eye with a patch for a prescribed period of time ranging from 10 minutes daily to all waking hours. However, its effectiveness decreases in older children and adults. Disadvantages include prolonged treatment leading to poor compliance, patching related distress, relationship strain and stigma. In extreme cases, non-compliance with patching results in a costly hospital admission to supervise the patching treatment. In addition, wearing a patch eliminates any advantage of binocularity. Not to mention that not all patients respond to patching and of those who do, many have residual amblyopia after treatment is stopped regardless of compliance. More importantly, binocular vision is not automatically restored once the vision in the amblyopic eye has been improved. In fact, once the patch is removed after therapy, the amblyopic eye could be suppressed by the better seeing eye and can lose some of the gains achieved as a result of therapy. Another modality of treatment is atropine eye drops and optical penalisation which are usually secondary treatments to failed patching but carrying the same disadvantages as the ordinary patching. Advances in amblyopia treatment include dichoptic training, perceptual learning, and video gaming. These depend on the fact that the adult brain has been shown to be much more plastic than it was once believed to be and hence have the advantage of expanding the age of response in adults. Perceptual learning approaches have the advantage of being a dichoptic (binocular treatment using both eyes) approach which is independent of age and type of amblyopia. A step further to conventional treatment is the use of a home-based approach allowing remote internet monitoring of treatment between office visits and hence better compliance. In addition a video game version of the treatment is developed to make it more enjoyable for improving compliance. Our goal is to compare the outcome between the gold standard occlusion therapy and one of the dichoptic treatments.

NCT ID: NCT03151200 Withdrawn - Amblyopia Clinical Trials

Visual Functional Connectivity and Visual Improvement After TMS/Binocular Treatment

Start date: January 30, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effectiveness of combining binocular treatment with repetitive transcranial magnetic stimulation (rTMS) in improving the vision of adults with amblyopia. This study also seeks to assess the effect of this combined treatment on cortical neural function and functional connectivity.